TM4SF1 and colonic neoplasm: After injection of a human-mouse chimeric monoclonal antibody against TM4SF1, 22.2% (4/18) of patients with breast cancer, colon cancer, or non-small cell lung cancer produced antibodies against antibody, and these aggregated around cancer cells [39].